Human leukocyte antigen peptide-binding groove (HLA peptide-binding groove)

The Human leukocyte antigen (HLA) peptide-binding groove is a specialized structural domain within Major Histocompatibility Complex (MHC) Class I and II molecules responsible for displaying short peptide fragments on the cell surface (Janeway et al., Immunobiology, 2001). This groove is formed by two alpha-helices resting on a floor of beta-strands, creating a pocket that accommodates peptides derived from either endogenous proteins or exogenous pathogens (Rock et al., Nature Immunology, 2016). In the context of modern immunotherapy, this site is a critical patient-specific target because HLA genes are the most polymorphic in the human genome, meaning the shape and chemical environment of the groove vary significantly between individuals (Yewdell, Nature Reviews Immunology, 2006). Therapeutic strategies like neoantigen vaccines (e.g., mRNA-4157) and TCR-engineered T-cells (e.g., Afamitresgene autoleucel) target the unique complex formed when a disease-associated peptide is nestled within a patient's specific HLA groove (Sahin & Türeci, Science, 2018). By recognizing these peptide-MHC (pMHC) complexes, the immune system can selectively eliminate malignant or infected cells while sparing healthy tissue. However, challenges include the potential for immune escape through HLA downregulation and the risk of off-target toxicity if the therapeutic agent recognizes similar peptides in healthy organs (Garrido et al., Cancer Immunology, Immunotherapy, 2016).

Other names

MHC peptide-binding cleftAntigen-binding grooveHLA binding pocketMajor histocompatibility complex binding sitepMHC complex

Facilitates the presentation of specific intracellular or extracellularly derived antigenic peptides to T-cell receptors (TCRs), thereby initiating a targeted cellular immune response (Janeway et al., Immunobiology, 2001).